170 related articles for article (PubMed ID: 31996744)
1. Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer.
Göthlin Eremo A; Lagergren K; Othman L; Montgomery S; Andersson G; Tina E
Sci Rep; 2020 Jan; 10(1):1451. PubMed ID: 31996744
[TBL] [Abstract][Full Text] [Related]
2. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
3. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
[TBL] [Abstract][Full Text] [Related]
4. FE65 defines the efficacy of tamoxifen treatment via osteopontin expression in estrogen receptor-positive breast cancer.
Xu J; Iwabuchi E; Miki Y; Kanai A; Takagi K; Suzuki T; Ishida T; Sasano H
Pathol Res Pract; 2022 Jun; 234():153898. PubMed ID: 35447603
[TBL] [Abstract][Full Text] [Related]
5. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study.
Collin LJ; Maliniak ML; Cronin-Fenton DP; Ahern TP; Christensen KB; Ulrichsen SP; Damkier P; Hamilton-Dutoit S; Yacoub R; Christiansen PM; Sørensen HT; Lash TL
Breast Cancer Res; 2021 Nov; 23(1):103. PubMed ID: 34736510
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients.
Klebaner D; Hamilton-Dutoit S; Ahern T; Crawford A; Jakobsen T; Cronin-Fenton DP; Damkier P; Janssen E; Kjaersgaard A; Ording AG; Søiland H; Sørensen HT; Lash TL; Hellberg Y
PLoS One; 2017; 12(3):e0171453. PubMed ID: 28301514
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
9. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.
Bramwell VH; Tuck AB; Chapman JA; Anborgh PH; Postenka CO; Al-Katib W; Shepherd LE; Han L; Wilson CF; Pritchard KI; Pollak MN; Chambers AF
Breast Cancer Res; 2014 Jan; 16(1):R8. PubMed ID: 24451146
[TBL] [Abstract][Full Text] [Related]
10. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
11. EXPRESSION OF SPP1 AND SPARC GENES IN TUMOR TISSUE OF PATIENTS WITH BREAST CANCER.
Chekhun V; Pavlova A; Zadvornyi T; Borikun T; Naleskina L; Mushii O; Bazas V; Lukianova N
Exp Oncol; 2024 May; 46(1):13-21. PubMed ID: 38852057
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin splice variants are differential predictors of breast cancer treatment responses.
Zduniak K; Agrawal A; Agrawal S; Hossain MM; Ziolkowski P; Weber GF
BMC Cancer; 2016 Jul; 16():441. PubMed ID: 27400751
[TBL] [Abstract][Full Text] [Related]
13. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
14. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.
Psyrri A; Kalogeras KT; Wirtz RM; Kouvatseas G; Karayannopoulou G; Goussia A; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Economopoulou P; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
J Transl Med; 2017 Feb; 15(1):30. PubMed ID: 28193231
[TBL] [Abstract][Full Text] [Related]
15. CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance.
Gao T; Han Y; Yu L; Ao S; Li Z; Ji J
PLoS One; 2014; 9(3):e91771. PubMed ID: 24622579
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin as a multifaceted driver of bone metastasis and drug resistance.
Pang X; Gong K; Zhang X; Wu S; Cui Y; Qian BZ
Pharmacol Res; 2019 Jun; 144():235-244. PubMed ID: 31028902
[TBL] [Abstract][Full Text] [Related]
17. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
18. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Habel LA; Shak S; Jacobs MK; Capra A; Alexander C; Pho M; Baker J; Walker M; Watson D; Hackett J; Blick NT; Greenberg D; Fehrenbacher L; Langholz B; Quesenberry CP
Breast Cancer Res; 2006; 8(3):R25. PubMed ID: 16737553
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma.
Ferreira LB; Eloy C; Pestana A; Lyra J; Moura M; Prazeres H; Tavares C; Sobrinho-Simões M; Gimba E; Soares P
Eur J Endocrinol; 2016 Apr; 174(4):551-61. PubMed ID: 26811408
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin: its potential role in cancer of children and young adults.
Karpinsky G; Fatyga A; Krawczyk MA; Chamera M; Sande N; Szmyd D; Izycka-Swieszewska E; Bien E
Biomark Med; 2017 Apr; 11(4):389-402. PubMed ID: 28326824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
